Table 1.
Characteristics of subjects providing peripheral blood
| Characteristics | Microarray analysis | Validation | ||||
|---|---|---|---|---|---|---|
|
| ||||||
| AECOPD (n=5) | Stable COPD (n=5) | Control (n=5) | AECOPD (n=51) | Stable COPD (n=51) | Control (n=30) | |
|
| ||||||
| Age (years) | 66.75±2.250 | 67.93±2.453 | 66.45±2.39 | 66.08±1.072 | 68.09±0.9601 | 67.04±0.932 |
| Sex (M/F) | 5/0 | 5/0 | 5/0 | 50/1 | 50/1 | 29/1 |
| Smoking (packs/year) | 38.72±3.723 | 37.28±2.670 | 35.24±2.12 | 36.00±2.382 | 36.76±1.872 | 34.52±1.934 |
| Smoking (total packs) | 360.6±63.72 | 323.9±58.18 | 377.2±51.76 | 390.2±53.42 | 387.5±37.64 | 342.5±49.64 |
| FEV1 | NA | 1.83±0.12a | 2.81±0.1 | NA | 1.93±0.09b | 2.75±0.1 |
| FEV1/predicted | NA | 54.12±3.29a | 92.84±2.53 | NA | 52.08±3.02b | 92.74±3.74 |
| FEV1/FVC | NA | 48.67±2.01a | 78.60±1.42 | NA | 49.72±1.53b | 79.23±1.45 |
Notes:
a
P<0.05 compared stable COPD with control in microarray analysis group;
b
P<0.05 compared stable COPD with control in validation group.
Abbreviations: NA, not available; AECOPD, acute exacerbation of COPD.